Ukr.Biochem.J. 2020; Volume 92, Issue 5, Sep-Oct, pp. 70-77

doi: https://doi.org/10.15407/ubj92.05.070

The oxidative status in patients with chronic kidney disease

V. S. Vasylchenko1,2*, L. V. Korol1, O. B. Kuchmenko2, N. M. Stepanova1

1State Institution “Institute of Nephrology of the National Academy
of Medical Sciences of Ukraine”, Kyiv;
2National University of Kyiv-Mohyla Academy, Ukraine;
*e-mail: vasylchenkovita@gmail.com

Received: 26 March 2020; Accepted: 25 June 2020

An excess of free radicals accompanies the development of renal pathologies and causes numerous concomitant complications and syndromes. The most common of these are cardiometabolic syndromes in patients with chronic kidney disease. Therefore, the purpose of the study was to determine the activity of paraoxonase-1 and myeloperoxidase, which are associated with indicators of high-density lipoproteins content and oxidative stress in the blood of patients with the chronic stage of kidney disease. The activity of the enzymes, thiobarbiturate-active products concentration and  transferrin, ceruloplasmin, thiol compounds content were determined in the blood of patients with chronic kidney disease. The oxidative status was shown to be changed. Thus, myeloperoxidase activity, the content of  oxidized proteins and the concentration of thiobarbiturate-positive components were increased, while  the activity of the antioxidant enzyme paraoxonase-1, the content of transferrin, ceruloplasmin and thiol compounds were decreased. The ratio of myeloperoxidase/paraoxonase-1 activities was progressively increased up to 9-fold, indicating the presence of cardiovascular complications in patients. The data obtained allowed to extend the range of indicators for monitoring the development of cardiometabolic disorders in the progression of chronic kidney disease.

Keywords: , , ,


References:

  1. Dincer N, Dagel T, Afsar B, Covic A, Ortiz A, Kanbay M. The effect of chronic kidney disease on lipid metabolism. Int Urol Nephrol. 2019;51(2):265-277. PubMed, CrossRef
  2. Korol LV, Mygal LYa, Stepanova NM. Intensity of oxidative stress and activity of angiotensin converting enzyme in blood of patients with uncomplicated pyelonephritis. Ukr Biochem J. 2017;89(2):99-105.  CrossRef
  3. Rysz J, Gluba-Brzózka A, Rysz-Górzyńska M, Franczyk B. The role and function of HDL in patients with chronic kidney disease and the risk of cardiovascular disease. Int J Mol Sci. 2020;21(2):601. PubMed, PubMedCentral,CrossRef
  4. Atamer A, Kocyigit Y, Ecder SA, Selek S, Ilhan N, Ecder T, Atamer Y. Effect of oxidative stress on antioxidant enzyme activities, homocysteine and lipoproteins in chronic kidney disease. J Nephrol. 2008;21(6):924-930. PubMed
  5. Efe TH, Ertem AG, Altunoglu A, Koseoglu C, Erayman A, Bilgin M, Kurmuş Ö, Aslan T, Bilge M. Serum paraoxonase levels are correlated with impaired aortic functions in patients with chronic kidney disease. Acta Cardiol Sin. 2016;32(1):75-80. PubMed, PubMedCentral
  6. Kuchmenko O, Mkhitaryan L, Kupchynska O, Ievstratova I, Vasylynchuk N, Matova O, Mostovyak M, Drobotko T. Protein factors of oxidative status and development of pathological state in patients with arterial hypertension. Visnyk Lviv Univ. Ser Biol. 2016;(73):303-309. (In Ukrainian).
  7. Teng N, Maghzal GJ, Talib J, Rashid I, Lau AK, Stocker R. The roles of myeloperoxidase in coronary artery disease and its potential implication in plaque rupture. Redox Rep. 2017;22(2):51-73. PubMed, PubMedCentral, CrossRef
  8. Murakami T, Okamoto H, Kim H. Structural and functional changes in high-density lipoprotein induced by chemical modification. Biomater Sci. 2015;3(5):712-715.  PubMed, CrossRef
  9. Manolescu BN, Berteanu M, Cintezã D. Effect of the nutritional supplement ALAnerv® on the serum PON1 activity in post-acute stroke patients. Pharmacol Rep. 2013;65(3):743-750. PubMed, CrossRef
  10. Gorudko IV, Cherkalina OS, Sokolov AV, Pulina MO, Zakharova ET, Vasil’e VB, Cherenkevich SN, Panasenko OM. New approaches to the measurement of the concentration and peroxidase activity of myeloperoxidase in human blood plasma. Bioorg Khim. 2009;35(5):629-639. (In Russian). PubMed, CrossRef
  11. Saeed SA, Elsharkawy M, Elsaeed K, Fooda O. Paraoxonase-1 (PON1) activity as a risk factor for atherosclerosis in chronic renal failure patients. Hemodial Int. 2008;12(4):471-479. PubMed, CrossRef
  12. Soria-Florido MT, Olga Castañer O, Lassale C, Estruch R, Salas-Salvadó J, Martínez-González  MÁ, Corella D, Ros E, Arós F, Elosua R, Lapetra J, Fiol M, Alonso-Gómez A, Gómez-Gracia  E, Serra-Majem L, Pintó X, Bulló M, Ruiz-Canela M, Sorlí JV, Hernáez Á, Fitó M. Dysfunctional high-Density Lipoproteins are associated with a greater incidence of acute coronary syndrome in a population at high cardiovascular risk: a nested case-control study. Circulation. 2020;141(6):444-453. PubMed, CrossRef
  13. Zhang H, Reilly MP. Novel mechanistic links between high-protein diets and atherosclerosis. Nat Metab. 2020;2(1):7-8. PubMed, CrossRef
  14. Herrington WG, Staplin N, Haynes R. Kidney disease trials for the 21st century: innovations in design and conduct. Nat Rev Nephrol. 2020;16(3):173-185. PubMed, PubMedCentral, CrossRef
  15. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med. 2011;17(11):1410-1422. PubMed, CrossRef
  16. Gugliucci A, Kotani K, Kimura S. Paraoxonase 1 in chronic kidney failure. J Lipids. 2012;2012:726048. PubMed, PubMedCentral, CrossRef
  17. Daenen K, Andries A, Mekahli D, Van Schepdael A, Jouret F, Bammens B. Oxidative stress in chronic kidney disease. Pediatr Nephrol. 2019;34(6):975-991. PubMed, CrossRef
  18. Sokolov AV, Kostevich VA, Gorbunov NV, Grigorieva DV, Gorudko IV, Vasilyev VB, Panasenko OM. A link between active myeloperoxidase and chlorinated ceruloplasmin in blood plasma of patients with cardiovascular diseases. Med Immunol (Russia). 2018; 20(5): 699-710. (In Russian).  CrossRef
  19. Yusova OI, Savchuk OV, Grinenko TV, Kuchmenko OB, Mhitaryan LS, Kupchins’ka OH, Yevstratov IN, Matova OO, Vasilinchuk NM, Drobot’ko TF. Determination of plasminogen/plasmin system components and indicators of lipoproteins oxidative modification under arterial hypertension. Ukr Biochem J. 2018; 90(1): 58-67.  CrossRef
  20. Miljkovic M, Stefanovic A, Vekic J, Zeljkovic A, Gojkovic T, Simic-Ogrizovic S, Bogavac-Stanojevic N, Cerne D, Ilic J, Stefanovic I, Jelic-Ivanovic Z, Spasojevic-Kalimanovska V, Kotur-Stevuljevic J. Activity of paraoxonase 1 (PON1) on HDL 2 and HDL 3 subclasses in renal disease. Clin Biochem. 2018;60:52-58. PubMed, CrossRef
  21. Deáková Z, Országhová Z, Andrezálová L, Slezák P, Lehotay J, Muchová J, Bürki C, Ďuračková Z. Influence of oak wood polyphenols on cysteine, homocysteine and glutathione total levels and PON1 activities in human adult volunteers – a pilot study. Gen Physiol Biophys. 2015;34(1):73-80. PubMed, CrossRef
  22. Hammadah M, Kalogeropoulos AP, Georgiopoulou VV, Weber M, Yuping Wu Y, Hazen SL, Butler J, Tang WHW. High-density lipoprotein-associated paraoxonase-1 activity for prediction of adverse outcomes in outpatients with chronic heart failure. Eur J Heart Fail. 2017;19(6):748-755. PubMed, PubMedCentral, CrossRef
  23. Prakash M, Shetty JK, Rao L, Sharma S, Rodrigues A, Prabhu R. Serum paraoxonase activity and protein thiols in chronic renal failure patients. Indian J Nephrol. 2008;18(1):13-16. PubMed, PubMedCentral, CrossRef
  24. Zhang R, Sung SHP, Feng G, Zhang CJ, Kenry, Tang BZ, Liu B. Aggregation-induced emission probe for specific turn-on quantification of soluble transferrin receptor: an important disease marker for iron deficiency anemia and kidney diseases. Anal Chem. 2018;90(2):1154-1160. PubMed, CrossRef
  25. Romanova Y, Laikov A, Markelova M, Khadiullina R, Makseev A, Hasanova M, Rizvanov A, Khaiboullina S, Salafutdinov I. Proteomic analysis of human serum from patients with chronic kidney disease. Biomolecules. 2020;10(2):257. PubMed, PubMedCentral, CrossRef
  26. Krzewicka-Romaniuk E, Siedlecka D, Warpas A, Wójcicka G. Paraoxonase 1 as an important antiatherogenic agent. J Educ Health Sport. 2019;9(1):133-143.
  27. Besarab A, Coyne DW. Iron supplementation to treat anemia in patients with chronic kidney disease. Nat Rev Nephrol. 2010;6(12):699-710. PubMed, CrossRef
  28. Gao M, Monian P, Quadri N, Ramasamy R, Jiang X. Glutaminolysis and transferrin regulate ferroptosis. Mol Cell. 2015;59(2):298-308. PubMed, PubMedCentral, CrossRef
  29. Przemysław W, Piotr K, Grażyna C, Danuta KP, Małgorzata I, Bernadeta M, Małgorzata S, Witold S. Total, free, and protein-bound thiols in plasma of peritoneal dialysis and predialysis patients. Int Urol Nephrol. 2011;43(4):1201-1209. PubMed, CrossRef
  30. Stepanova N, Korol L, Burdeyna O. Oxidative stress in peritoneal dialysis patients: association with the dialysis adequacy and technique survival. Indian J Nephrol. 2019;29(5):309-316. PubMed, PubMedCentral, CrossRef

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.